Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: Improved prognosis in triple-negative tumors

Drugs in R and D

Volumn 11, Issue 2, 2011, Pages 147-157

  Medioni, Jacques ^a,b   Huchon, Cyrille ^a,b   Le Frere Belda, Marie Aude ^a   Hofmann, Henri ^a,c   Bats, Anne Sophie ^a,b   Eme, Denise ^a   Andrieu, Jean Marie ^a,b   Oudard, Stéphane ^a,b   Lecuru, Fabrice ^a,b   Levy, Eric ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Clinique Saint Jean de Dieu   (France)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Gemcitabine; Vinorelbine

Indexed keywords

DOCETAXEL; EPIRUBICIN; GEMCITABINE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 79959459260     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11591210-000000000-00000     Document Type: Article

References (29)

1. Bafaloukos D. Neo-adjuvant therapy in breast cancer. Ann Oncol 2005; 16 Suppl. 2: ii174-81 (Pubitemid 40908953)
2. Hennessy B, Hanrahan E, Valero V. Neoadjuvant therapy of breast cancer. Am J Cancer 2006; 5: 411-25
3. Van Praagh I, Cure H, Leduc B, et al. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. Oncologist 2002; 7: 418-23 (Pubitemid 35266134)
4. Mieog J, van der Hage J, van de Velde C. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007 Apr 18; (2): CD005002
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34 (Pubitemid 47219710)
6. Liu Z, Liu G, Yang W, et al. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Rep 2008; 20: 987-94
7. Rakha EA, El-SayedME,GreenAR, et al. Prognosticmarkers in triple-negative breast cancer. Cancer 2007; 109: 25-32
8. Tian XS, Cong MH, Zhou WH, et al. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008; 31: 610-4
9. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502 (Pubitemid 43854964)
10. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007; 7: 203
11. Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 2008; 26: 1275-81
12. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533-9
13. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34 (Pubitemid 46698581)
14. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85 (Pubitemid 41170290)
15. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44 (Pubitemid 46291713)
16. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 2003; 21: 1431-9 (Pubitemid 46594092)
17. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-62
18. Schneeweiss A, Huober J, Sinn HP, et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur J Cancer 2004; 40: 2432-8 (Pubitemid 39424957)
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10 (Pubitemid 19099520)
20. European Organisation for Research and Treatment of Cancer. RECIST version 10 2000 [online]. Available from URL: http://www.eortc.be/Recist/ Default.htm [Accessed 2009 Dec 17]
21. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2009; 28: 2784-95
22. National Cancer Institute. Common Toxicity Criteria Manual 1 June 1999 version 20 [online]. Available from URL: nic-applications/docs/ctcv20-4-30- 992pdf [Accessed 2008 Dec 17]
23. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 2008; 26: 778-85 (Pubitemid 351264391)
24. Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995; 26: 873-9
25. Chua S, Smith IE, Aern RP, et al. Neoadjuvant vinorelbine/ epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)Ann Oncol 2005; 16: 1435-41 (Pubitemid 41222415)
26. Conte PF, Donati S, Gennari A, et al. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. Br J Cancer 2005; 93: 406-11 (Pubitemid 43080013)
27. Fountzilas G, Skarlos D, Dafni U, et al. Postoperative dosedense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with highrisk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 1762-71 (Pubitemid 41631238)
28. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a doseintensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21: 843-50 (Pubitemid 46606444)
29. Mehta RS. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox [letter]. J Clin Oncol 2008; 26: 3286-8; author reply 3288